Takafumi Tsuboi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5944009/publications.pdf

Version: 2024-02-01

209 papers 7,675 citations

50276 46 h-index 72 g-index

221 all docs

221 docs citations

times ranked

221

7508 citing authors

#	Article	IF	CITATIONS
1	Detection of Four Plasmodium Species by Genus- and Species-Specific Loop-Mediated Isothermal Amplification for Clinical Diagnosis. Journal of Clinical Microbiology, 2007, 45, 2521-2528.	3.9	248
2	Identification and Prioritization of Merozoite Antigens as Targets of Protective Human Immunity to <i>Plasmodium falciparum</i> Malaria for Vaccine and Biomarker Development. Journal of Immunology, 2013, 191, 795-809.	0.8	213
3	Wheat Germ Cell-Free System-Based Production of Malaria Proteins for Discovery of Novel Vaccine Candidates. Infection and Immunity, 2008, 76, 1702-1708.	2.2	203
4	Preerythrocytic, live-attenuated <i>Plasmodium falciparum</i> vaccine candidates by design. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13004-13009.	7.1	164
5	Antibodies to Malaria Vaccine Candidates Pvs25 and Pvs28 Completely Block the Ability of Plasmodium vivax To Infect Mosquitoes. Infection and Immunity, 2000, 68, 6618-6623.	2.2	160
6	Rhoptry neck protein RON2 forms a complex with microneme protein AMA1 in Plasmodium falciparum merozoites. Parasitology International, 2009, 58, 29-35.	1.3	159
7	Biosynthesis, Localization, and Macromolecular Arrangement of the Plasmodium falciparum Translocon of Exported Proteins (PTEX). Journal of Biological Chemistry, 2012, 287, 7871-7884.	3.4	130
8	PfSET10, a Plasmodium falciparum Methyltransferase, Maintains the Active var Gene in a Poised State during Parasite Division. Cell Host and Microbe, 2012, 11, 7-18.	11.0	124
9	Plasmodium vivax transmission: chances for control?. Trends in Parasitology, 2004, 20, 192-198.	3.3	122
10	Immune evasion of Plasmodium falciparum by RIFIN via inhibitory receptors. Nature, 2017, 552, 101-105.	27.8	118
11	Functional Comparison of Plasmodium falciparum Transmission-Blocking Vaccine Candidates by the Standard Membrane-Feeding Assay. Infection and Immunity, 2013, 81, 4377-4382.	2.2	117
12	Sequence Polymorphism in Two Novel Plasmodium vivax Ookinete Surface Proteins, Pvs25 and Pvs28, That Are Malaria Transmission-blocking Vaccine Candidates. Molecular Medicine, 1998, 4, 772-782.	4.4	108
13	Immunoproteomics Profiling of Blood Stage <i>Plasmodium vivax</i> Infection by High-Throughput Screening Assays. Journal of Proteome Research, 2010, 9, 6479-6489.	3.7	104
14	Artemisinin <i>⟨i⟩Resistant<i>Plasmodium falciparum</i>with High Survival Rates, Uganda, 2014–2016. Emerging Infectious Diseases, 2018, 24, 718-726.</i>	4.3	104
15	von Willebrand Factor A Domain-related Protein, a novel microneme protein of the malaria ookinete highly conserved throughout Plasmodium parasites. Molecular and Biochemical Parasitology, 2001, 116, 65-72.	1.1	96
16	Development and validation of serological markers for detecting recent Plasmodium vivax infection. Nature Medicine, 2020, 26, 741-749.	30.7	90
17	Plasmodium Ookinete-secreted Proteins Secreted through a Common Micronemal Pathway Are Targets of Blocking Malaria Transmission. Journal of Biological Chemistry, 2004, 279, 26635-26644.	3.4	87
18	The high molecular mass rhoptry protein, RhopH1, is encoded by members of the clag multigene family in Plasmodium falciparum and Plasmodium yoelii. Molecular and Biochemical Parasitology, 2001, 118, 223-231.	1.1	85

#	Article	IF	Citations
19	New Insights into Acquisition, Boosting, and Longevity of Immunity to Malaria in Pregnant Women. Journal of Infectious Diseases, 2012, 206, 1612-1621.	4.0	85
20	A Plant-Produced Pfs230 Vaccine Candidate Blocks Transmission of Plasmodium falciparum. Vaccine Journal, 2011, 18, 1351-1357.	3.1	84
21	Natural Acquisition of Immunity to Plasmodium vivax. Advances in Parasitology, 2013, 81, 77-131.	3.2	84
22	N-Terminal Prodomain of Pfs230 Synthesized Using a Cell-Free System Is Sufficient To Induce Complement-Dependent Malaria Transmission-Blocking Activity. Vaccine Journal, 2011, 18, 1343-1350.	3.1	82
23	Development of Malaria Transmission-Blocking Vaccines: From Concept to Product. Advances in Parasitology, 2015, 89, 109-152.	3.2	82
24	Evidence for the Transmission of Plasmodium vivaxin the Republic of the Congo, West Central Africa. Journal of Infectious Diseases, 2009, 200, 1465-1469.	4.0	81
25	The Plasmodium falciparum clag9 gene encodes a rhoptry protein that is transferred to the host erythrocyte upon invasion. Molecular Microbiology, 2004, 52, 107-118.	2.5	78
26	Host immunity to <i>Plasmodium falciparum</i> and the assessment of emerging artemisinin resistance in a multinational cohort. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3515-3520.	7.1	78
27	Single amino acid substitution in <i>Plasmodium yoelii</i> erythrocyte ligand determines its localization and controls parasite virulence. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7167-7172.	7.1	76
28	Targets of complement-fixing antibodies in protective immunity against malaria in children. Nature Communications, 2019, 10, 610.	12.8	76
29	Autophagy-Related Atg8 Localizes to the Apicoplast of the Human Malaria Parasite Plasmodium falciparum. PLoS ONE, 2012, 7, e42977.	2.5	75
30	Gene structure and expression of a Plasmodium falciparum 220-kDa protein homologous to the Plasmodium vivax reticulocyte binding proteins. Molecular and Biochemical Parasitology, 2002, 121, 275-278.	1.1	73
31	Apical expression of three RhopH1/Clag proteins as components of the Plasmodium falciparum RhopH complex. Molecular and Biochemical Parasitology, 2005, 143, 20-28.	1.1	73
32	Evaluation of Loop-Mediated Isothermal Amplification (LAMP) for Malaria Diagnosis in a Field Setting. American Journal of Tropical Medicine and Hygiene, 2011, 85, 594-596.	1.4	73
33	Multiple Plasmodium falciparum Merozoite Surface Protein 1 Complexes Mediate Merozoite Binding to Human Erythrocytes. Journal of Biological Chemistry, 2016, 291, 7703-7715.	3.4	70
34	Discovery of GAMA, a Plasmodium falciparum Merozoite Micronemal Protein, as a Novel Blood-Stage Vaccine Candidate Antigen. Infection and Immunity, 2011, 79, 4523-4532.	2.2	69
35	Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development. ELife, 2017, 6, .	6.0	64
36	Plasmodium vivax:Favored Gene Frequencies of the Merozoite Surface Protein-1 and the Multiplicity of Infection in a Malaria Endemic Region. Experimental Parasitology, 1996, 83, 11-18.	1.2	63

#	Article	IF	CITATIONS
37	Nasal Immunization with a Malaria Transmission-Blocking Vaccine Candidate, Pfs25, Induces Complete Protective Immunity in Mice against Field Isolates of Plasmodium falciparum. Infection and Immunity, 2005, 73, 7375-7380.	2.2	63
38	Transmission-blocking vaccine of vivax malaria. Parasitology International, 2003, 52, 1-11.	1.3	60
39	Molecular Analysis of <i>Plasmodium ovale </i> Variants. Emerging Infectious Diseases, 2004, 10, 1235-1240.	4.3	60
40	The association between naturally acquired IgG subclass specific antibodies to the PfRH5 invasion complex and protection from Plasmodium falciparum malaria. Scientific Reports, 2016, 6, 33094.	3.3	59
41	Plasmodium Merozoite TRAP Family Protein Is Essential for Vacuole Membrane Disruption and Gamete Egress from Erythrocytes. Cell Host and Microbe, 2016, 20, 618-630.	11.0	59
42	The wheat germ cell-free protein synthesis system: A key tool for novel malaria vaccine candidate discovery. Acta Tropica, 2010, 114, 171-176.	2.0	55
43	Profiling the humoral immune responses to Plasmodium vivax infection and identification of candidate immunogenic rhoptry-associated membrane antigen (RAMA). Journal of Proteomics, 2014, 102, 66-82.	2.4	55
44	Antibody profiles to wheat germ cell-free system synthesized Plasmodium falciparum proteins correlate with protection from symptomatic malaria in Uganda. Vaccine, 2017, 35, 873-881.	3.8	55
45	Development of a reverse transcription-loop-mediated isothermal amplification (RT-LAMP) for clinical detection of Plasmodium falciparum gametocytes. Parasitology International, 2010, 59, 414-420.	1.3	54
46	Reemerging vivax malaria: changing patterns of annual incidence and control programs in the Republic of Korea. Korean Journal of Parasitology, 2006, 44, 285.	1.3	54
47	Naturally acquired antibody responses to more than 300 Plasmodium vivax proteins in three geographic regions. PLoS Neglected Tropical Diseases, 2017, 11, e0005888.	3.0	52
48	Plasmodium vivax gametocyte proteins, Pvs48/45 and Pvs47, induce transmission-reducing antibodies by DNA immunization. Vaccine, 2015, 33, 1901-1908.	3.8	51
49	BLOCKING OF TRANSMISSION TO MOSQUITOES BY ANTIBODY TO PLASMODIUM VIVAX MALARIA VACCINE CANDIDATES PVS25 AND PVS28 DESPITE ANTIGENIC POLYMORPHISM IN FIELD ISOLATES. American Journal of Tropical Medicine and Hygiene, 2003, 69, 536-541.	1.4	51
50	Immunoscreening of Plasmodium falciparum proteins expressed in a wheat germ cell-free system reveals a novel malaria vaccine candidate. Scientific Reports, 2017, 7, 46086.	3.3	50
51	Control of Cell Wall Assembly by a Histone-Like Protein in Mycobacteria. Journal of Bacteriology, 2007, 189, 8241-8249.	2.2	48
52	Identification of Plasmodium malariae, a Human Malaria Parasite, in Imported Chimpanzees. PLoS ONE, 2009, 4, e7412.	2.5	48
53	Serological markers to measure recent changes in malaria at population level in Cambodia. Malaria Journal, 2016, 15, 529.	2.3	48
54	Sterile Protection against Plasmodium knowlesi in Rhesus Monkeys from a Malaria Vaccine: Comparison of Heterologous Prime Boost Strategies. PLoS ONE, 2009, 4, e6559.	2.5	46

#	Article	IF	CITATIONS
55	Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate. Vaccine, 2012, 30, 1807-1812.	3.8	46
56	Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission. Vaccine, 2010, 28, 6014-6020.	3.8	45
57	Characterisation of the rhoph2 gene of Plasmodium falciparum and Plasmodium yoelii. Molecular and Biochemical Parasitology, 2003, 127, 47-57.	1.1	43
58	Diversity and evolution of the rhoph $1/c$ lag multigene family of Plasmodium falciparum. Molecular and Biochemical Parasitology, 2008, 158, $11-21$.	1.1	42
59	<i>Plasmodium vivax</i> Ookinete Surface Protein Pvs25 Linked to Cholera Toxin B Subunit Induces Potent Transmission-Blocking Immunity by Intranasal as Well as Subcutaneous Immunization. Infection and Immunity, 2010, 78, 3773-3782.	2.2	42
60	The Plasmodium vivax Merozoite Surface Protein 1 Paralog Is a Novel Erythrocyte-Binding Ligand of P. vivax. Infection and Immunity, 2013, 81, 1585-1595.	2.2	42
61	An Efficient Approach to the Production of Vaccines Against the Malaria Parasite. Methods in Molecular Biology, 2010, 607, 73-83.	0.9	41
62	The Plasmodium vivax homolog of the ookinete adhesive micronemal protein, CTRP. Parasitology International, 2006, 55, 227-231.	1.3	39
63	Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration. Vaccine, 2011, 29, 9038-9050.	3.8	39
64	Plasmodium vivax: comparison of immunogenicity among proteins expressed in the cell-free systems of Escherichia coli and wheat germ by suspension array assays. Malaria Journal, 2011, 10, 192.	2.3	39
65	Identification of a reticulocyte-specific binding domain of Plasmodium vivax reticulocyte-binding protein 1 that is homologous to the PfRh4 erythrocyte-binding domain. Scientific Reports, 2016, 6, 26993.	3.3	39
66	The Wheat Germ Cell-Free Expression System. Methods in Molecular Biology, 2005, 310, 131-144.	0.9	39
67	Micronemal Transport of Plasmodium Ookinete Chitinases to the Electron-Dense Area of the Apical Complex for Extracellular Secretion. Infection and Immunity, 2000, 68, 6461-6465.	2.2	38
68	Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes. Vaccine, 2003, 21, 3143-3148.	3.8	38
69	RALP1 Is a Rhoptry Neck Erythrocyte-Binding Protein of Plasmodium falciparum Merozoites and a Potential Blood-Stage Vaccine Candidate Antigen. Infection and Immunity, 2013, 81, 4290-4298.	2.2	38
70	Serological Surveillance Development for Tropical Infectious Diseases Using Simultaneous Microsphere-Based Multiplex Assays and Finite Mixture Models. PLoS Neglected Tropical Diseases, 2014, 8, e3040.	3.0	38
71	Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28â€"evaluation of homologous and heterologous antigen-delivery prime-boost strategy. Vaccine, 2004, 22, 3205-3213.	3.8	37
72	Enzymatic characterization of the Plasmodium vivax chitinase, a potential malaria transmission-blocking target. Parasitology International, 2009, 58, 243-248.	1.3	37

#	Article	IF	Citations
73	Loop-Mediated Isothermal Amplification Assay for Rapid Diagnosis of Malaria Infections in an Area of Endemicity in Thailand. Journal of Clinical Microbiology, 2014, 52, 1471-1477.	3.9	37
74	Identification of domains within Pfs230 that elicit transmission blocking antibody responses. Vaccine, 2019, 37, 1799-1806.	3.8	37
75	Application of wheat germ cell-free protein expression system for novel malaria vaccine candidate discovery. Expert Review of Vaccines, 2014, 13, 75-85.	4.4	36
76	Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development. PLoS ONE, 2015, 10, e0136109.	2.5	36
77	Detection of Plasmodium vivax infection in the Republic of Korea by loop-mediated isothermal amplification (LAMP). Acta Tropica, 2010, 113, 61-65.	2.0	35
78	Worldwide sequence conservation of transmission-blocking vaccine candidate Pvs230 in Plasmodium vivax. Vaccine, 2011, 29, 4308-4315.	3.8	35
79	Pv12, a 6-Cys antigen of Plasmodium vivax, is localized to the merozoite rhoptry. Parasitology International, 2012, 61, 443-449.	1.3	35
80	Targeting Sialic Acid Dependent and Independent Pathways of Invasion in Plasmodium falciparum. PLoS ONE, 2012, 7, e30251.	2.5	35
81	Plasmodial ortholog of Toxoplasma gondii rhoptry neck protein 3 is localized to the rhoptry body. Parasitology International, 2011, 60, 132-138.	1.3	33
82	Characteristic Age Distribution of Plasmodium vivax Infections after Malaria Elimination on Aneityum Island, Vanuatu. Infection and Immunity, 2014, 82, 243-252.	2.2	33
83	Nitric oxide inhibits the development of Plasmodium yoelii gametocytes into gametes. Parasitology International, 1998, 47, 157-166.	1.3	32
84	A small-scale systematic analysis of alternative splicing in Plasmodium falciparum. Parasitology International, 2009, 58, 196-199.	1.3	32
85	Rhoptry neck protein 2 expressed in Plasmodium sporozoites plays a crucial role during invasion of mosquito salivary glands. Cellular Microbiology, 2019, 21, e12964.	2.1	32
86	2-Cys Peroxiredoxin TPx-1 is involved in gametocyte development in Plasmodium berghei. Molecular and Biochemical Parasitology, 2006, 148, 44-51.	1.1	31
87	Antibodies against a Plasmodium falciparum antigen PfMSPDBL1 inhibit merozoite invasion into human erythrocytes. Vaccine, 2012, 30, 1972-1980.	3.8	31
88	Two types of Plasmodium ovale defined by SSU rRNA have distinct sequences for ookinete surface proteins. Molecular and Biochemical Parasitology, 2002, 122, 223-226.	1.1	30
89	Pyruvate kinase type-II isozyme in Plasmodium falciparum localizes to the apicoplast. Parasitology International, 2009, 58, 101-105.	1.3	29
90	Functional characterization of Plasmodium berghei PSOP25 during ookinete development and as a malaria transmission-blocking vaccine candidate. Parasites and Vectors, 2017, 10, 8.	2.5	29

#	Article	IF	Citations
91	PV1, a novel Plasmodium falciparum merozoite dense granule protein, interacts with exported protein in infected erythrocytes. Scientific Reports, 2018, 8, 3696.	3.3	29
92	Cell-free synthesis, reconstitution, and characterization of a mitochondrial dicarboxylate–tricarboxylate carrier of Plasmodium falciparum. Biochemical and Biophysical Research Communications, 2011, 414, 612-617.	2.1	28
93	Immunoprofiling of the Tryptophan-Rich Antigen Family in Plasmodium vivax. Infection and Immunity, 2015, 83, 3083-3095.	2.2	28
94	Plasmodium vivax GPI-anchored micronemal antigen (PvGAMA) binds human erythrocytes independent of Duffy antigen status. Scientific Reports, 2016, 6, 35581.	3.3	28
95	Expression profiles of peroxiredoxin proteins of the rodent malaria parasite Plasmodium yoelii. International Journal for Parasitology, 2003, 33, 1455-1461.	3.1	27
96	Identification of three ookinete-specific genes and evaluation of their transmission-blocking potentials in Plasmodium berghei. Vaccine, 2016, 34, 2570-2578.	3.8	26
97	Serologic Markers in Relation to Parasite Exposure History Help to Estimate Transmission Dynamics of Plasmodium vivax. PLoS ONE, 2011, 6, e28126.	2.5	26
98	A Small Molecule Glycosaminoglycan Mimetic Blocks Plasmodium Invasion of the Mosquito Midgut. PLoS Pathogens, 2013, 9, e1003757.	4.7	25
99	Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate. Vaccine, 2016, 34, 5612-5622.	3.8	25
100	A male gametocyte osmiophilic body and microgamete surface protein of the rodent malaria parasitePlasmodium yoelii(PyMiGS) plays a critical role in male osmiophilic body formation and exflagellation. Cellular Microbiology, 2018, 20, e12821.	2.1	25
101	Molecular Camouflage of Plasmodium falciparum Merozoites by Binding of Host Vitronectin to P47 Fragment of SERA5. Scientific Reports, 2018, 8, 5052.	3.3	25
102	Primary structure of a novel ookinete surface protein from Plasmodium berghei1Note: Nucleotide sequence data reported in this paper are available in the EMBL, GenBankâ, $^{\circ}$ and DDBJ data bases under the accession number D88664.1. Molecular and Biochemical Parasitology, 1997, 85, 131-134.	1.1	24
103	Molecular test for vivax malaria with loop-mediated isothermal amplification method in central China. Parasitology Research, 2012, 110, 2439-2444.	1.6	24
104	Characterization of a novel merozoite surface protein of Plasmodium vivax, Pv41. Acta Tropica, 2013, 126, 222-228.	2.0	24
105	Absence of in vivo selection for K13 mutations after artemether–lumefantrine treatment in Uganda. Malaria Journal, 2017, 16, 23.	2.3	24
106	The Plasmodium falciparum RhopH2 promoter and first 24 amino acids are sufficient to target proteins to the rhoptries. Parasitology International, 2007, 56, 31-43.	1.3	23
107	Serodiagnostic applicability of recombinant antigens of Clonorchis sinensis expressed by wheat germ cell-free protein synthesis system. Diagnostic Microbiology and Infectious Disease, 2009, 64, 334-339.	1.8	23
108	Differences in PfEMP1s recognized by antibodies from patients with uncomplicated or severe malaria. Malaria Journal, 2016, 15, 258.	2.3	23

#	Article	IF	CITATIONS
109	Recovery and stable persistence of chloroquine sensitivity in Plasmodium falciparum parasites after its discontinued use in Northern Uganda. Malaria Journal, 2020, 19, 76.	2.3	23
110	Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine. Vaccine, 2011, 29, 2720-2726.	3.8	22
111	Measurement of naturally acquired humoral immune responses against the C-terminal region of the Plasmodium vivax MSP1 protein using protein arrays. Parasitology Research, 2011, 109, 1259-1266.	1.6	22
112	Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 8 in patients with P. vivax infection. Malaria Journal, 2017, 16, 211.	2.3	22
113	Disruption of the Plasmodium berghei 2-Cys peroxiredoxin TPx-1 gene hinders the sporozoite development in the vector mosquito. Molecular and Biochemical Parasitology, 2008, 159, 142-145.	1.1	21
114	Malaria vaccine candidates displayed on novel virus-like particles are immunogenic and induce transmission-blocking activity. PLoS ONE, 2019, 14, e0221733.	2.5	21
115	Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates. American Journal of Tropical Medicine and Hygiene, 2003, 69, 536-41.	1.4	21
116	Development of a Method for the In Vitro Production of Plasmodium vivax Ookinetes. Journal of Parasitology, 2001, 87, 928-930.	0.7	20
117	Erythrocyte surface glycosylphosphatidyl inositol anchored receptor for the malaria parasite. Molecular and Biochemical Parasitology, 2005, 140, 13-21.	1.1	20
118	Large-scale survey for novel genotypes of Plasmodium falciparum chloroquine-resistance gene pfcrt. Malaria Journal, 2012, 11, 92.	2.3	20
119	Vaccine candidates for malaria: what's new?. Expert Review of Vaccines, 2016, 15, 1-3.	4.4	20
120	Blood-stage malaria vaccines: post-genome strategies for the identification of novel vaccine candidates. Expert Review of Vaccines, 2017, 16, 769-779.	4.4	20
121	Gene structure and ookinete expression of the chitinase genes of Plasmodium vivax and Plasmodium yoelii. Molecular and Biochemical Parasitology, 2003, 130, 51-54.	1.1	19
122	Comprehensive analysis of antibody responses to Plasmodium falciparum erythrocyte membrane protein 1 domains. Vaccine, 2018, 36, 6826-6833.	3.8	19
123	Plasmodium falciparum Exported Protein 1 is localized to dense granules in merozoites. Parasitology International, 2018, 67, 637-639.	1.3	19
124	Deletion of Plasmodium falciparum Protein RON3 Affects the Functional Translocation of Exported Proteins and Glucose Uptake. MBio, 2019, 10, .	4.1	19
125	Comparison of Plasmodium yoelii ookinete surface antigens with human and avian malaria parasite homologues reveals two highly conserved regions 1 Note: Nucleotide sequence data reported in this paper are available in the EMBL, GenBankâ,, and DDBJ data bases under the accession numbers: Pys21, D89081 and Pys25, D89082.1. Molecular and Biochemical Parasitology, 1997, 87, 107-111.	1.1	18
126	Presence of three distinct ookinete surface protein genes, Pos25, Pos28-1, and Pos28-2, in Plasmodium ovale. Molecular and Biochemical Parasitology, 2001, 113, 341-344.	1.1	18

#	Article	lF	Citations
127	The N-terminal segment of Plasmodium falciparum SURFIN4.1 is required for its trafficking to the red blood cell cytosol through the endoplasmic reticulum. Parasitology International, 2013, 62, 215-229.	1.3	18
128	Phenotypic Dissection of a Plasmodium-Refractory Strain of Malaria Vector Anopheles stephensi: The Reduced Susceptibility to P. berghei and P. yoelii. PLoS ONE, 2013, 8, e63753.	2.5	18
129	Adeno-Associated Virus as an Effective Malaria Booster Vaccine Following Adenovirus Priming. Frontiers in Immunology, 2019, 10, 730.	4.8	18
130	Leveraging the wheat germ cell-free protein synthesis system to accelerate malaria vaccine development. Parasitology International, 2021, 80, 102224.	1.3	18
131	Conserved regions of the Plasmodium yoelii rhoptry protein RhopH3 revealed by comparison with the P. falciparum homologue. Molecular and Biochemical Parasitology, 2001, 112, 297-299.	1.1	17
132	Plasmodium vivax serine repeat antigen (SERA) multigene family exhibits similar expression patterns in independent infections. Molecular and Biochemical Parasitology, 2006, 150, 353-358.	1.1	17
133	Tricomponent Immunopotentiating System as a Novel Molecular Design Strategy for Malaria Vaccine Development. Infection and Immunity, 2011, 79, 4260-4275.	2.2	17
134	A member of the CPW-WPC protein family is expressed in and localized to the surface of developing ookinetes. Malaria Journal, 2013, 12, 129.	2.3	17
135	Antigenicity studies in humans and immunogenicity studies in mice: an MSP1P subdomain as a candidate for malaria vaccine development. Microbes and Infection, 2014, 16, 419-428.	1.9	16
136	A rapid genotyping method for the vivax malaria transmission-blocking vaccine candidates, Pvs25 and Pvs28. Parasitology International, 2004, 53, 211-216.	1.3	15
137	Cell-free production of functional Plasmodium falciparum dihydrofolate reductase-thymidylate synthase. Molecular and Biochemical Parasitology, 2007, 151, 216-219.	1.1	15
138	Global Repertoire of Human Antibodies Against Plasmodium falciparum RIFINs, SURFINs, and STEVORs in a Malaria Exposed Population. Frontiers in Immunology, 2020, 11, 893.	4.8	15
139	A comparison of non-magnetic and magnetic beads for measuring IgG antibodies against Plasmodium vivax antigens in a multiplexed bead-based assay using Luminex technology (Bio-Plex 200 or MAGPIX). PLoS ONE, 2020, 15, e0238010.	2.5	15
140	Immunogenicity and antigenicity of Plasmodium vivax merozoite surface protein 10. Parasitology Research, 2014, 113, 2559-2568.	1.6	14
141	Characterization of Plasmodium berghei Pbg37 as Both a Pre- and Postfertilization Antigen with Transmission-Blocking Potential. Infection and Immunity, 2018, 86, .	2.2	14
142	Rhoptry neck protein 11 has crucial roles during malaria parasite sporozoite invasion of salivary glands and hepatocytes. International Journal for Parasitology, 2019, 49, 725-735.	3.1	14
143	Expression and Localization Profiles of Rhoptry Proteins in Plasmodium berghei Sporozoites. Frontiers in Cellular and Infection Microbiology, 2019, 9, 316.	3.9	14
144	Antibodies against a short region of PfRipr inhibit Plasmodium falciparum merozoite invasion and PfRipr interaction with Rh5 and SEMA7A. Scientific Reports, 2020, 10, 6573.	3.3	14

#	Article	IF	Citations
145	The malaria parasite Plasmodium falciparum in red blood cells selectively takes up serum proteins that affect host pathogenicity. Malaria Journal, 2020, 19, 155.	2.3	14
146	Biological effects of Spirometra erinacei plerocercoids in several species of rodents. Zeitschrift F $\tilde{A}\frac{1}{4}$ r Parasitenkunde (Berlin, Germany), 1983, 69, 489-499.	0.8	13
147	Malaria Ookinete Surface Protein-Based Vaccination via the Intranasal Route Completely Blocks Parasite Transmission in both Passive and Active Vaccination Regimens in a Rodent Model of Malaria Infection. Infection and Immunity, 2009, 77, 5496-5500.	2.2	13
148	Maternal-foetal transfer of Plasmodium falciparum and Plasmodium vivax antibodies in a low transmission setting. Scientific Reports, 2016, 6, 20859.	3.3	13
149	Identification of a novel merozoite surface antigen of Plasmodium vivax, PvMSA180. Malaria Journal, 2017, 16, 133.	2.3	13
150	The N-Terminal Region of Plasmodium falciparum MSP10 Is a Target of Protective Antibodies in Malaria and Is Important for PfGAMA/PfMSP10 Interaction. Frontiers in Immunology, 2019, 10, 2669.	4.8	13
151	Identification of Novel Malaria Transmission-Blocking Vaccine Candidates. Frontiers in Cellular and Infection Microbiology, 2021, 11, 805482.	3.9	13
152	Serological responses to a soluble recombinant chimeric Plasmodium vivax circumsporozoite protein in VK210 and VK247 population. Malaria Journal, 2013, 12, 323.	2.3	12
153	Genetic diversity of transmission-blocking vaccine candidate Pvs48/45 in Plasmodium vivax populations in China. Parasites and Vectors, 2015, 8, 615.	2.5	12
154	Naturally-acquired cellular immune response against Plasmodium vivax merozoite surface protein-1 paralog antigen. Malaria Journal, 2015, 14, 159.	2.3	12
155	Identification of target proteins of clinical immunity to Plasmodium falciparum in a region of low malaria transmission. Parasitology International, 2018, 67, 203-208.	1.3	12
156	PfMSA180 is a novel Plasmodium falciparum vaccine antigen that interacts with human erythrocyte integrin associated protein (CD47). Scientific Reports, 2019, 9, 5923.	3.3	12
157	Elucidating functional epitopes within the N-terminal region of malaria transmission blocking vaccine antigen Pfs230. Npj Vaccines, 2022, 7, 4.	6.0	12
158	Genetic Polymorphism of Plasmodium vivax msp1p, a Paralog of Merozoite Surface Protein 1, from Worldwide Isolates. American Journal of Tropical Medicine and Hygiene, 2011, 84, 292-297.	1.4	10
159	Antibody titre as a surrogate of protection of the first malaria subunit vaccine, RTS,S/AS01. Lancet Infectious Diseases, The, 2015, 15, 1371-1372.	9.1	10
160	Plasmodium falciparum: Genetic diversity and complexity of infections in an isolated village in western Thailand. Parasitology International, 2015, 64, 260-266.	1.3	10
161	Observation of morphological changes of female osmiophilic bodies prior to Plasmodium gametocyte egress from erythrocytes. Molecular and Biochemical Parasitology, 2020, 236, 111261.	1.1	10
162	Plasmodium vivax transmission-blocking vaccines: Progress, challenges and innovation. Parasitology International, 2022, 87, 102525.	1.3	10

#	Article	IF	CITATIONS
163	Mucosal vaccination approach against mosquito-borne Japanese encephalitis virus. Japanese Journal of Infectious Diseases, 2009, 62, 37-45.	1.2	10
164	Gametocyte-dominant expression of a novel P-type ATPase in Plasmodium yoelii. Molecular and Biochemical Parasitology, 1999, 104, 331-336.	1.1	9
165	Identification and characterization of the Plasmodium falciparum RhopH2 ortholog in Plasmodium vivax. Parasitology Research, 2013, 112, 585-593.	1.6	9
166	Naturally-Acquired Immune Response against Plasmodium vivax Rhoptry-Associated Membrane Antigen. PLoS ONE, 2016, 11, e0148723.	2.5	9
167	The Plasmodium yoelii microgamete surface antigen (PyMiGS) induces anti-malarial transmission blocking immunity that reduces microgamete motility/release from activated male gametocytes. Vaccine, 2018, 36, 7463-7471.	3.8	9
168	Application of 23 Novel Serological Markers for Identifying Recent Exposure to Plasmodium vivax Parasites in an Endemic Population of Western Thailand. Frontiers in Microbiology, 2021, 12, 643501.	3.5	9
169	Characterization of Plasmodium vivax Early Transcribed Membrane Protein 11.2 and Exported Protein 1. PLoS ONE, 2015, 10, e0127500.	2.5	9
170	Wheat germ cell-free technology for accelerating the malaria vaccine research. Expert Opinion on Drug Discovery, 2009, 4, 1191-1199.	5.0	8
171	Antigenicity and immunogenicity of PvRALP1, a novel Plasmodium vivax rhoptry neck protein. Malaria Journal, 2015, 14, 186.	2.3	8
172	Imaging of the subsurface structures of "unroofed―Plasmodium falciparum-infected erythrocytes. Experimental Parasitology, 2015, 153, 174-179.	1.2	8
173	Identification of a PH domain-containing protein which is localized to crystalloid bodies of Plasmodium ookinetes. Malaria Journal, 2018, 17, 466.	2.3	8
174	Malaria transmission-blocking vaccines: wheat germ cell-free technology can accelerate vaccine development. Expert Review of Vaccines, 2019, 18, 1017-1027.	4.4	8
175	Antibodies against a Plasmodium falciparum RON12 inhibit merozoite invasion into erythrocytes. Parasitology International, 2019, 68, 87-91.	1.3	8
176	Characterization of mitochondrial carrier proteins of malaria parasite Plasmodium falciparum based on in vitro translation and reconstitution. Parasitology International, 2020, 79, 102160.	1.3	8
177	A conserved malaria parasite antigen Pb22 plays a critical role in male gametogenesis in Plasmodium berghei. Cellular Microbiology, 2021, 23, e13294.	2.1	8
178	IgG Antibody Responses Are Preferential Compared With IgM for Use as Serological Markers for Detecting Recent Exposure to <i>Plasmodium vivax</i> Infection. Open Forum Infectious Diseases, 2021, 8, ofab228.	0.9	8
179	Comparison of Isozyme Patterns between Spirometra erinacei and Spirometra mansonoides by Isoelectric Focusing. Journal of Parasitology, 1992, 78, 735.	0.7	7
180	Plasmodium RON12 localizes to the rhoptry body in sporozoites. Parasitology International, 2019, 68, 17-23.	1.3	7

#	Article	IF	CITATIONS
181	Skeleton binding protein 1 (SBP1) of Plasmodium falciparum accumulates in electron-dense material before passing through the parasitophorous vacuole membrane. Parasitology International, 2020, 75, 102003.	1.3	7
182	Naturally acquired antibody kinetics against Plasmodium vivax antigens in people from a low malaria transmission region in western Thailand. BMC Medicine, 2022, 20, 89.	5.5	7
183	Stage-Specific Expression of Heat Shock Protein 90 in Murine Malaria Parasite Plasmodium yoelii. Experimental Parasitology, 1999, 93, 61-65.	1.2	6
184	Antibody responses to Plasmodium falciparum and Plasmodium vivax blood-stage and sporozoite antigens in the postpartum period. Scientific Reports, 2016, 6, 32159.	3.3	6
185	Progress toward a transmission-blocking vaccine against malaria. Lancet Infectious Diseases, The, 2018, 18, 927-928.	9.1	6
186	Plasmodium falciparum SURFIN4.1 forms an intermediate complex with PTEX components and Pf113 during export to the red blood cell. Parasitology International, 2021, 83, 102358.	1.3	6
187	Plasmodium vivax malaria serological exposure markers: Assessing the degree and implications of cross-reactivity with P.Âknowlesi. Cell Reports Medicine, 2022, 3, 100662.	6.5	6
188	Tricomponent Complex Loaded with a Mosquito-Stage Antigen of the Malaria Parasite Induces Potent Transmission-Blocking Immunity. Vaccine Journal, 2014, 21, 561-569.	3.1	5
189	Anti-MSP11 IgG inhibits Plasmodium falciparum merozoite invasion into erythrocytes in vitro. Parasitology International, 2019, 69, 25-29.	1.3	5
190	Identification of a Novel RAMA/RON3 Rhoptry Protein Complex in Plasmodium falciparum Merozoites. Frontiers in Cellular and Infection Microbiology, 2020, 10, 605367.	3.9	5
191	Asexual Blood-Stage Malaria Vaccine Candidate PfRipr5: Enhanced Production in Insect Cells. Frontiers in Bioengineering and Biotechnology, 0, 10, .	4.1	5
192	Molecular cloning and characterization of plerocercoid-immunosuppressive factor from Spirometra erinaceieuropaei. Parasitology International, 2020, 76, 102062.	1.3	4
193	Plasmodium yoelii Erythrocyte Binding Like Protein Interacts With Basigin, an Erythrocyte Surface Protein. Frontiers in Cellular and Infection Microbiology, 2021, 11, 656620.	3.9	4
194	Serodiagnostic antigens of Clonorchis sinensis identified and evaluated by high-throughput proteogenomics. PLoS Neglected Tropical Diseases, 2020, 14, e0008998.	3.0	4
195	Identifying Targets of Protective Antibodies against Severe Malaria in Papua, Indonesia, Using Locally Expressed Domains of Plasmodium falciparum Erythrocyte Membrane Protein 1. Infection and Immunity, 2022, 90, IAI0043521.	2.2	3
196	Evidence of the growth factor in mouse serum infected withSpirometra erinacei plerocercoids. Zeitschrift Für Parasitenkunde (Berlin, Germany), 1986, 72, 83-87.	0.8	2
197	Plasmodium berghei XAT: Protective 155/160kDa antigens are located in parasitophorous vacuoles of schizont-stage parasite. Experimental Parasitology, 2007, 116, 450-457.	1.2	2
198	The malaria parasite RhopH protein complex interacts with erythrocyte calmyrin identified from a comprehensive erythrocyte protein library. Biochemical and Biophysical Research Communications, 2018, 500, 261-267.	2.1	2

#	Article	IF	CITATIONS
199	The C-terminal region of the Plasmodium yoelii microgamete surface antigen PyMiGS induces potent anti-malarial transmission-blocking immunity in mice. Vaccine, 2020, 38, 3129-3136.	3.8	2
200	Characterization of a Plasmodium falciparum PHISTc protein, PF3D7_0801000, in blood-stage malaria parasites. Parasitology International, 2021, 80, 102240.	1.3	2
201	Comparison of total immunoglobulin G antibody responses to different protein fragments of Plasmodium vivax Reticulocyte binding protein 2b. Malaria Journal, 2022, 21, 71.	2.3	2
202	Effect of infection with Spirometra erinacei plerocercoid on thyroid hormone in mice. Parasitology Research, 1988, 74, 262-266.	1.6	1
203	Infected host serum blocks transmission of Plasmodium yoelii via a nitric oxide-dependent mechanism. Parasitology International, 1998, 47, 225-232.	1.3	1
204	The rodent malaria lactate dehydrogenase assay provides a high throughput solution for in vivo vaccine studies. Parasitology International, 2015, 64, 60-63.	1.3	1
205	Antibody Responses to Plasmodium falciparum and Plasmodium vivax and Prospective Risk of Plasmodium spp. Infection Postpartum. American Journal of Tropical Medicine and Hygiene, 2017, 96, 1197-1204.	1.4	1
206	Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study. Frontiers in Cellular and Infection Microbiology, 2022, 12, 804470.	3.9	1
207	AGIA Tag System for Ultrastructural Protein Localization Analysis in Blood-Stage Plasmodium falciparum. Frontiers in Cellular and Infection Microbiology, 2021, 11, 777291.	3.9	1
208	Editorial on the special issue on Plasmodium vivax: Current situation and challenges towards elimination. Parasitology International, 2022, 89, 102594.	1.3	1
209	Meta-Analysis of Human Antibodies Against Plasmodium falciparum Variable Surface and Merozoite Stage Antigens. Frontiers in Immunology, 0, 13 , .	4.8	1